Brolucizumab for Wet Aged-Related Macular Degeneration Patients : too Good to be True Oral Presentation - Observational Study - Resident
Article Sidebar
-
anti-vascular endothelial growth factor therapy, brolucizumab, wet age-related macular degeneration
Abstract
Introduction & Objectives
Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF). It showed superior
anatomic outcomes and noninferiority best corrected visual acuity (BCVA) results for Wet Aged-
Related Macular Degeneration (Wet-AMD) compared to other anti-VEGF. In Yogyakarta, it's been
only used in a few patients and we want to report the effectiveness and safety of brolucizumab in
WetAMD
Methods
In this retrospective study, all wetAMD patients who underwent Brolucizuab intravitreal injections
between December 2021 and January 2023 at Dr YAP Eye Hospital were studied. Patient’s
demographic data, before and after intravitreal brolucizumab injections (central macular thickness,
intraocular pressure, and BCVA) were assessed.
Results
This study included 6 eyes of 6 patients (3 women) with a mean age of 69.5 years old. The mean
follow-up period was 27 ± 10.1 weeks after the first injection of brolucizumab. Three patients were
naïve wetAMD patients, three anti-VEGF experienced wetAMD patients. The mean BCVA at baseline
(before brolucizumab injection) was 0.12 decimal (6/48) and 0.29 decimal (6/20) at the last followup.
Five out of six patients' visual acuity were improved. In four out of six patient central macular
thickness were reduced (mean difference 29,2 um). None of the patient's intraocular pressure
increased over 21 mmHg. None of the patients reported any signs of inflammation, vasculitis, ocular
or systemic adverse effects.
Conclusion
This limited data demonstrated that brolucizumab was relatively safe and effective in stabilizing
BCVA for both WetAMD patients who had previous treatment with other anti-VEGF agents and
naive. Larger sample sizes studies & future multicenter collaborative are warranted
Full text article
References
Brad H. Feldman, M.D., Vinay A. Shah M.D., Vinay A. Shah M.D., Leo A. Kim, MD, PhD, Koushik Tripathy, MD (AIIMS), FRCS (Glasgow), Jonathan C. Tsui, MD, Yasser M. Elshatory M. Age-Related Macular Degeneration. In: American Academy of Ophtalmology. 2022.
Tien Wong, MD P, Usha Chakravarthy, MD P, Ronald Klein, MD M, Paul Mitchell, MD P, Gergana Zlateva P, Ronald Buggage M, et al. The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2008;115(116–126).
Wolf AT, Harris A, Oddone F, Siesky B, Verticchio Vercellin A, Ciulla TA. Disease progression pathways of wet AMD: opportunities for new target discovery. Expert Opin Ther Targets. 2022;26(1):5–12.
Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab—early realworld experience: BREW study. Eye [Internet]. 2021;35(4):1045–7. Available from: http://dx.doi.org/10.1038/s41433-020-1111-x
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-erfurth U, Brown DM, et al. HAWK and HARRIER?: Phase 3 , Multicenter , Randomized , Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology [Internet]. 2020;127(1):72–84. Available from: https://doi.org/10.1016/j.ophtha.2019.04.017
Thomas CJ, Mirza RG, Gill MK, Frcs C. Age-Related Macular Degeneration. Med Clin NA [Internet]. 2021;105(3):473–91. Available from: https://doi.org/10.1016/j.mcna.2021.01.003
Schmidt-Erfurth U, Chong V, Loewenstein A et al. Guidelines for the management of neovascular agerelated macular degeneration by the European Society of Retina Specialists. Br J Ophthalmol. 2014;98:114467.
Boulanger-Scemama E, Querques G, About F et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to followup in a real-life setting. J Fr Ophtalmol. 2015;38:6207.
Ferrante N, Ritrovato D, Bitonti R, Furneri G. Costeffectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular agerelated macular degeneration (nAMD) in Italy. BMC Health Serv Res [Internet]. 2022;22(1):1–11. Available from: https://doi.org/10.1186/s12913-022-07972-w
Authors
Copyright (c) 2023 Tania Purbonegoro, M. Eko Prayogo, A. Nurini Agni, Tri Wahyu W., Supanji, Firman S. W., M.B Sasongko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.